14-3-3σ modulates pancreatic cancer cell survival and invasiveness

Clinical Cancer Research

Volumn 14, Issue 23, 2008, Pages 7614-7623

  Neupane, Divas ^a   Korc, Murray ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR; ISOPROTEIN; MESSENGER RNA; SHORT HAIRPIN RNA; SOMATOMEDIN C; STRATIFIN; PROTEIN 14 3 3;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INVASION; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; NUCLEOTIDE SEQUENCE; PANCREAS CARCINOMA; PANCREAS CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; CELL SURVIVAL; DRUG RESISTANCE; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOBLOTTING; METABOLISM; PANCREAS TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

14-3-3 PROTEINS; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 59449095125     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1366     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002;2:897-909.
3. Korc M. Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am 1998;7:25-41.
4. Westphal S, Kalthoff H. Apoptosis: targets in pancreatic cancer. Mol Cancer 2003;2:6.
5. Arnold NB, Ketterer K, Kleeff J, Friess H, Buchler MW, Korc M. Thioredoxin is downstream of Smad7 in a pathway that promotes growth and suppresses cis-platin-induced apoptosis in pancreatic cancer. Cancer Res 2004;64:3599-606.
6. Fu H, Subramanian RR, Masters SC. 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharma-col Toxicol 2000;40:617-47.
7. Rubio MP, Geraghty KM, Wong BH, et al. 14-3-3-af-finity purification of over 200 human phosphoproteins reveals new links to regulation of cellular metabolism, proliferation and trafficking. Biochem J 2004;379:395-408.
8. Muslin AJ, Tanner JW, Allen PM, Shaw AS. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 1996;84: 889-97.
9. Hermeking H. The 14-3-3 cancer connection. Nat Rev Cancer 2003;3:931-43.
10. Ferguson AT, Evron E, Umbricht CB, et al. High frequency of hypermethylation at the 14-3-3a locus leads to gene silencing in breast cancer. Proc Nat
11. cad Sci U S A 2000;97:6049-54.
12. Iwata N, Yamamoto H, Sasaki S, et al. Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3σ gene in human hepatocellular carcinoma. Oncogene 2000;19:5298-302.
13. Friess H, Ding J, Kleeff J, et al. Microarray-based identification of differentially expressed growth-and metastasis-associated genesin pancreaticcancer. Cell Mol Life Sci 2003;60:1180-99.
14. Logsdon CD, Simeone DM, Binkley C, et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differen-tially regulated in pancreatic cancer. Cancer Res 2003;63:2649-57.
15. NakamuraT, Furukawa Y, Nakagawa H, et al. Genome-wide c DNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. Oncogene 2004;23:2385-400.
16. lacobuzio-Donahue CA, Ashfaq R, Maitra A, et al. Highly expressed genes in pancreatic ductal adeno-carcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 2003;63:8614-22.
17. Perathoner A, Pirkebner D, Brandacher G, et al. 14-3-3σ expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Clin Cancer Res 2005;11:3274-9.
18. Villaret DB, Wang T, Dillon D, et al. Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis. Laryngoscope 2000;110:374-81.
19. Kleeff J, Korc M. Up-regulation of transforming growth factor (TGF)-β receptors by TGF-βin COLO-357 cells. J Biol Chem 1998;273:7495-500.
20. Ketterer K, Rao S, Friess H, Weiss J, Buchler MW, Korc M. Reverse transcription-PCR analysis of laser-captured cells points to potential paracrine and auto-crine actions of neurotrophins in pancreatic cancer. Clin Cancer Res 2003;9:5127-36.
21. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phe-nol-chloroform extraction. Anal Biochem 1987;162:156-9.
22. Yasutome M, Gunn J, Korc M. Restoration of Smad4 in BxPC3 pancreatic cancer cells attenuates proliferation without altering angiogenesis. Clin Exp Metastasis 2005;22:461-73.
23. Raitano AB, Korc M. Tumor necrosis factor up-regu-lates γ-interferon binding in a human carcinoma cell line. J Biol Chem1990;265:10466-72.
24. Baldwin RL, Korc M. Growth inhibition of human pancreatic carcinoma cells by transforming growth factor Growth Factors 1993;8:23-34.
25. Rowland-Goldsmith MA, Maruyama H, Kusama T, Ralli S, Korc M. Soluble type II transforming growth fac-tor-β (TGF-β) receptor inhibitsTGF-hβsignaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. Clin Cancer Res2001;7:2931-40.
26. 2/M reg-ulator14-3-3σ prevents apoptosis through sequestration of Bax. J Biol Chem 2001;276:45201-6.
27. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature 1999;401:616-20.
28. 2/M progression. Mol Cell 1997;1:3-11.
29. Cheng L, Pan CX, Zhang JT, et al. Loss of 14-3-3σ in prostate cancer and its precursors. Clin Cancer Res 2004;10:3064-8.
30. Lodygin D, Diebold J, Hermeking H. Prostate cancer is characterized by epigenetic silencing of 14-3-3σ expression. Oncogene 2004;23:9034-41.
31. UranoT, SaitoT,Tsukui T, et al. Efp targets 14-3-3σ for proteolysis and promotes breast tumour growth. Nature 2002;417:871-5.
32. Guweidhi A, Kleeff J, Giese N, et al. Enhanced expression of 14-3-3σ in pancreatic cancer and its role in cell cycle regulation and apoptosis. Carcinogenesis 2004;25:1575-85.
33. Seki T, Ohba N, Makino R, Funatomi H, Mitamura K. Mechanism of growth-inhibitory effect of cisplatin on human pancreatic cancer cellsand status of p53 gene. Anticancer Res 2001;21:1919-24.
34. Sato N, Maitra A, Fukushima N, et al. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res 2003;63:4158-66.
35. Wilker EW, Grant RA, Artim SC,Yaffe MB. A structural basis for 14-3-3σ functional specificity. J Biol Chem 2005;280:18891-8.
36. Zha J, Harada H,Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in re sponse to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996;87:619-28.
37. Nomura M, Shimizu S, Sugiyama T, et al. 14-3-3 interacts directly with and negatively regulates pro-apoptotic Bax. J Biol Chem 2003;278:2058-65.
38. Sinha P, Hutter G, Kottgen E, Dietel M, Schadendorf D, Lage H. Increased expression of epidermal fatty ac-id binding protein, cofilin, and 14-3-3σ (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas. Elec-trophoresis1999;20:2952-60.
39. LiuY,LiuH,HanB,ZhangJT.Identificationof14-3-3σ as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis. Cancer Res 2006;66:3248-55.
40. Keleg S, Buchler P, Ludwig R, Buchler MW, Friess H. Invasion and metastasis in pancreatic cancer. Mol Cancer 2003;2:14.
41. Rowland-Goldsmith MA, Maruyama H, Matsuda K, et al. Soluble type II transforming growth factor-β receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis. Mol CancerTher 2002;1:161-7.
42. AikawaT,Whipple CA, Lopez ME, et al. Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells. J Clin Invest 2008;118:89-99.
43. Ciardiello F,Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-74.
44. Normanno N, Bianco C, De Luca A, Salomon DS. The role of EGF-related peptides in tumor growth. Front Biosci 2001;6:D685-707.
45. Li J, Kleeff J, Giese N, Buchler MW, Korc M, Friess H. Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhib-its pancreatic cancer cell growth, invasion, and colony formation. IntJ Oncol 2004;25:203-10.
46. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M. Coexpression of epidermal growth factor receptorand ligands in human pancreatic cancerisas-sociated with enhanced tumor aggressiveness. Anti-cancer Res1993;13:565-9.
47. SummyJM,TrevinoJG, Baker CH, Gallick GE. c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK. Pancreas 2005;31:263-74.
48. Trevino JG, Summy JM, Lesslie DP, et al. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarci-noma cells in an orthotopic nude mouse model. Am J Pathol 2006;168:962-72.
49. Ghahary A, Karimi-Busheri F, Marcoux Y, et al. Kera-tinocyte-releasable stratifin functions as a potent col-lagenase-stimulating factor in fibroblasts. J Invest Dermatol 2004;122:1188-97.
50. Ghahary A, Marcoux Y, Karimi-Busheri F, et al. Differentiated keratinocyte-releasable stratifin (14-3-3σ) stimulates MMP-1 expression in dermal fibroblasts. J Invest Dermatol 2005;124:170-7.